Positive immunohistochemical expression of bcl-2 in hormone-independent breast carcinomas is associated with a greater lymph node involvement and poor outcome

Medical Oncology

Volumn 31, Issue 8, 2014, Pages

  Ruibal, Álvaro ^a,b,c   Aguiar, Pablo ^a,b,d   Del Río, María Carmen ^e   Menéndez, Primitiva ^f   Arias, José Ignacio ^f   Herranz, Michel ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c Fundacion Tejerina   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e General Laboratory Hospital Virgen Da Xunqueira   (Spain)

^f Hospital Monte del Naranco   (Spain)

Author keywords

bcl 2; ER; Hormone independent breast cancer; PgR

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; HORMONE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; AR PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER MORTALITY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84903856573     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0105-6     Document Type: Article

References (23)

1. Abdel-Fatah TMA, Perry C, Dixkinson P, Ball G, Moseley P, Madhusudan S, Elli IO, et al. Bcl-2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol. 2013;24:2801-7.
2. Azad N, Iyer A, Vallyathan V, Wang L, Castranova V, Stehlik C, Rpjanasakuul Y. Role of oxidative(nitrosative stress -mediated Bcl-2 regulation in apoptosis and malignant transformation. Ann NY Acad Sci. 2010;1203:1-6.
3. Basu A, Haldar S. The relationship between bcl-2, bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reproduct. 1998;4:1099-109. (Pubitemid 28552792)
4. Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL-2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008;8:153.
5. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. Bcl-2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010;103:668-75.
6. Dueñas-González A, Abad-Hernández MM, Cruz-Hernández JJ, González-Sarmiento R. Analysis of bcl-2 in sporadic breast carcinoma. Cancer. 1997;80:2100-8. (Pubitemid 27506023)
7. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994;54:2095-209.
8. Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK, Moon HG, et al. Prognostic influence of Bcl-2 expression in breast cancer. Int J Cancer. 2012;131:1109-19.
9. Hyndi M, Sorensen FB, Knudsen H, Alsner J, Overgaard M, Nielsen HM, et al. Impact of bcl-2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c. Acta Oncol. 2008;47:608-17. (Pubitemid 351878461)
10. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, et al. Reduced expression of proapoptotic gene bax is associated with poor responde and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995;55:4471-8.
11. Lacle MM, van der Pol C, Witkamp A, van der Wall E, van Diest PJ. Prognostic value of mitotic index and bcl-2 expression in male breast cancer. PLoS ONE. 2013;8:e60138.
12. Li L, Backer J, Annisa S, Wong SK, Schwanke EL, Stewart BG, et al. Bcl-2 expression decreases cadherin-mediated cell-cell adhesion. J Cell Sci. 2003;116:3687-700. (Pubitemid 37185298)
13. Luna-Moré S, Weil B, Bautista D, Garrido E, Florez P, Martínez C. Bcl-2 protein in normal, hyperplastic and neoplastic breast tissues. A metabolite of the putative stem-cell subpopulation of the mammary gland. Histoll Histopathol. 2004;19:457-63. (Pubitemid 38443907)
14. Martínez Arribas F, Alvarez T, Del Val G, Martín Garabato E, Nuñez Villar MJ, Lucas R, et al. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res. 2007;27:219-22. (Pubitemid 46363335)
15. Naumovski L, Cleary MI. The p53-binding protein 53BP2 also interacts with Bcl-2 and impedes cell cycle progression at G2/M. Mol Cell Biol. 1996;16:3884-92. (Pubitemid 26199908)
16. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, et al. Sensitization of BCl-2 expressing breast tumors to chemotherapy by the BH3mimetic ABT-737. Proc Natl Acad Sci USA. 2012;109:2766-71.
17. Saxena N, Katiyar SP, Liu Y, Grover A, Gao R, Sundar D, Kaul SC, Wandhwa R. Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization. Biosci Rep. 2013;33(5):e00073.
18. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node positive breast cancer patients. J Clin Oncol. 1996;14:1604-10. (Pubitemid 26134219)
19. Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Segio CM, Gallego-Ortega D, et al. Bcl-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Mol Cancer Ther. 2013;12:1874-85.
20. Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors. Hum Pathol. 2012;43:23-30.
21. Teixeira C, Reed JC, Partt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 1995;55:3902-7.
22. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein Ch, et al. Rp53, but not tumor-derived mutants, bind to bcl-2 via DNA binding domain and induces mitochondrial permeabilization. J Biol Chem. 2006;281:8600-6. (Pubitemid 43847963)
23. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene. 2001;20:240-51. (Pubitemid 32150269)